Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm, Yale University Extend Collaboration

Published: Wednesday, May 07, 2014
Last Updated: Wednesday, May 07, 2014
Bookmark and Share
New license and research agreement regarding the discovery of MIF inhibitors.

Debiopharm Group™ (Debiopharm) has announced that it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

This joint effort will enable the discovery and development of potential oral first-in-class compounds that inhibit Macrophage Migration Inhibitory Factor (MIF), a key regulatory cytokine that has been linked genetically to the pathogenesis of several autoimmune and inflammatory diseases.

“We are very pleased to announce this new research collaboration with top-ranked Yale University. We are convinced that building a strong relationship with leading, medically-focused academic institutions is a productive way of creating drugs for tomorrow” said Thierry Mauvernay, Delegate of the Board, Debiopharm Group.

Yale researchers Richard Bucala, MD, PhD, Professor of Medicine, Epidemiology and Pathology, and William L. Jorgensen, PhD, Sterling Professor of Chemistry and Director of the Division of Physical Sciences and Engineering, are leading the Yale scientific team designing small molecule antagonists to block inflammation in patients.

“Debiopharm’s reputation for early stage drug development is well known, and this is an exciting new therapeutic approach that may ultimately allow us to tailor treatment to a patient’s immunogenetic profile,” said Bucala.

“The project is progressing well with great synergies between computer-aided molecular design, synthetic chemistry, crystallography and biology,” Jorgensen added. “We are delighted with Debiopharm's participation, which is essential for spearheading the preclinical and clinical efforts.”

"This is a great example of how scientists of academia and industry can put their efforts together to bring solutions to pressing medical needs in a more efficient manner" added Andrés McAllister, Chief Scientific Officer, Debiopharm International SA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Go To Market Consulting and Debiopharm Collaborate
Collaboration to identify early stage in-licensing opportunities on the US West Coast.
Friday, September 27, 2013
Scientific News
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!